Spine society assesses adoption of conflicts of interest policies

Spine society assesses adoption  of conflicts of interest policies
The North American Spine Society has adopted strict divestment and disclosure policies with no detrimental effects, according to research published online Oct. 22 in The Spine Journal.

(HealthDay)—The North American Spine Society (NASS) has adopted strict divestment and disclosure policies with no detrimental effects, according to research published online Oct. 22 in The Spine Journal.

Jerome A. Schofferman, M.D., from the Care Institute of San Francisco, and colleagues describe the experience of the NASS in implementing comprehensive conflicts of interest policies, focusing on conflicts of interest as they apply to professional medical associations rather than individual physicians.

The researchers found that NASS has managed its financial relationships with industry in a manner that has minimized influence and bias. NASS's current policies of disclosure and divestment have had no detrimental impact on membership, annual meeting attendance, finances, or leadership recruitment.

"The NASS experience can provide a template for other professional medical associations to help manage their own possible conflicts of interest issues," the authors write.

One author disclosed consulting relationships with companies that manufacture for the treatment of spinal disorders.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Cambodia bans 'virgin surgery' adverts

22 hours ago

The Cambodian government has ordered a hospital to stop advertising so-called virginity restoration procedures, saying it harms the "morality" of society.

What's happening with your donated specimen?

Jan 28, 2015

When donating blood, plasma, human tissue or any other bodily sample for medical research, most people might not think about how it's being used. But if you were told, would you care?

Amgen tops Street 4Q forecasts

Jan 27, 2015

Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.